Eric Boodman
Eric Boodman is a general assignment reporter at STAT, focusing on narrative features. He has written about various topics since joining the company in 2015 and has received numerous awards for his work. His stories have been recognized with the American Society of Magazine Editors' 'Next' Award for Journalists Under 30, the Evert Clark/Seth Payne Award for Young Science Journalists, the Science in Society Award, and the Deborah Howell Award for Writing Excellence. Boodman enjoys in-person reporting and exploring insects. He began his journalism career while still in high school, reviewing bird books for the Montreal Gazette.
97%
The Daily's Verdict
This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.
Bias
100%
Examples:
No current examples available.
Conflicts of Interest
100%
Examples:
No current examples available.
Contradictions
100%
Examples:
No current examples available.
Deceptions
94%
Examples:
- Taking a Tylenol was like using a squirt gun against a house fire.
- That she couldn't have the pain medicine she usually got for a sickle cell crisis because she was six weeks pregnant, but she could have Tylenol.
Recent Articles
New Gene Therapies and Innovative Approaches: Advancing Treatments for Sickle Cell Disease
Broke On: Tuesday, 21 May 2024Two new gene therapies for sickle cell disease, approved in fall 2023, offer hope for a functional cure but raise questions about accessibility and equity. Researchers also explore alternative treatments like stem cell transplants from umbilical cord blood and small molecules that modulate gene expression. The goal is to develop accessible, effective, and equitable treatments for sickle cell disease. New Gene Therapies and Innovative Approaches: Advancing Treatments for Sickle Cell Disease
Broke On: Tuesday, 21 May 2024Two new gene therapies for sickle cell disease, approved in fall 2023, offer hope for a functional cure but raise questions about accessibility and equity. Researchers also explore alternative treatments like stem cell transplants from umbilical cord blood and small molecules that modulate gene expression. The goal is to develop accessible, effective, and equitable treatments for sickle cell disease.